Immedica welcomes Heidi Ramstad as new Chief Medical Officer


It is with great pleasure we can announce that Heidi Ramstad has been offered and accepted the position as Chief Medical Officer (CMO) at Immedica Pharma.

Heidi is a Medical Doctor (MD) and Specialist in Pediatric Medicine. She has many years of academic and pharmaceutica industry experience. As an example, she has Medical Affairs experience from both big and small pharma, eg. being country and Nordic medical director for companies such as Pfizer, GSK and Roche. Recently she has held the position as CMO at the Swedish Biopharma company Oasmia.

We are very glad to bring Heidi onboard, and she will be an important contributor for the many activities and projects currently underway at Immedica.

Heidi will start her new role at Immedica at in April 2022 and she will report to Immedica CEO Anders Edvell. She will also be a member of the Immedica Executive Leadership Team.


About Immedica AB
Immedica is a fast-growing private niche pharma group with headquarter in Stockholm, Sweden and commercial coverage across Europe and the Middle East. Immedica has significant know-how and experience in commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution.

Immedica’ s main owner is Impilo AB, a private Nordic investment company established in 2017.
More information is available at

Chief Executive Officer
Phone:  +46 705446126